Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 7 peer-reviewed journal articles Updated
Ophthalmology

Who Is Eligible for LHON Gene Therapy Trials (Lumevoq)?

At a Glance

Historical Lumevoq trials focused on people with LHON caused by the m.11778G>A mutation who were treated within one year of vision loss; the primary study populations were at least 15 years old when vision loss began, but current eligibility depends on each trial’s protocol and medical screening.

If you are reading about Lumevoq (lenadogene nolparvovec), an investigational gene therapy for Leber hereditary optic neuropathy (LHON), it is important to understand its current status. Lumevoq is not currently an approved, widely available treatment. Much of what we know about who might be eligible for future gene therapies comes from completed historical clinical trials, specifically the RESCUE and REVERSE trials. In those studies, researchers focused on a very specific group: patients who had the m.11778G>A mutation and who were in the early stages of vision loss, having been treated within one year of symptom onset [1].

The Right Mutation: m.11778G>A

LHON can be caused by several different mitochondrial genetic mutations. Lumevoq was specifically developed and studied in patients who have the m.11778G>A mutation in the MT-ND4 gene [2][3].

Investigational gene therapies like Lumevoq do not repair or remove your inherited mutation. Instead, they use a delivery vehicle (called a vector) to add a functional, engineered copy of the target gene into the cells of the eye [4][5]. Because Lumevoq delivers a copy of the ND4 gene, it is designed to work only if ND4 is the gene that is malfunctioning [4]. If your LHON is caused by a different mutation—such as m.14484T>C or m.3460G>A—this specific gene therapy will not target the underlying cause of your vision loss, and you would not be a candidate for trials studying Lumevoq [5].

Historical Trial Guidelines: Timing and Age

In the major completed trials for Lumevoq, researchers set strict rules about how long a patient could have experienced vision loss before receiving the investigational treatment. These were protocol-specific study windows, not absolute rules about when a treatment might theoretically work.

  • The RESCUE trial studied patients whose vision loss had begun up to 6 months prior [2].
  • The REVERSE trial studied patients whose vision loss had been ongoing for approximately 6 to 12 months [3].

Together, these trials evaluated the therapy in patients treated within one year of their vision loss beginning [1][6]. The timeline clock typically starts based on when symptoms first appeared in the first affected eye. Additionally, the primary analyzed populations in these pivotal studies were at least 15 years old at the onset of their disease [1]. Future clinical trials may use different age or timing requirements.

Assessing the Health of the Optic Nerve

The strict timelines in past trials were designed to test the therapy before the optic nerve underwent substantial, irreversible thinning. LHON causes retinal ganglion cells (the cells and nerve fibers that transmit visual information to the brain) to become damaged.

In post-study analyses, researchers found an association: patients who received the therapy when they still had better baseline visual acuity and thicker retinal nerve layers tended to have better final visual outcomes [7]. Doctors use Optical Coherence Tomography (OCT), a non-invasive imaging scan, to measure the thickness of these nerve fiber layers [7]. While OCT scans help doctors assess the structural health of your optic nerve, one thin measurement does not automatically disqualify you from future research.

Evaluating Risks and Alternative Options

Having the correct mutation and symptom timeline does not guarantee enrollment in a trial. Participating in gene therapy research involves an intravitreal injection (an injection into the eye). This carries potential risks, including eye inflammation and other procedure-related complications, and the long-term benefits remain uncertain.

If you are not eligible for a specific trial, or if there are no actively enrolling trials in your region, it does not mean you are without options. Depending on your location and specific condition, other management strategies—such as the medication idebenone, avoidance of mitochondrial triggers like smoking, genetic counseling, and low-vision rehabilitation—may be available to support your daily life.

Next Steps for Patients

If you want to explore whether you might qualify for any actively recruiting trials, you and your medical team will need to compile:

  • Genetic Confirmation: An official genetic test result confirming the m.11778G>A mutation.
  • Symptom Timeline: Your best estimate, supported by medical records or personal notes, of when vision changes began in your first affected eye.

Common questions in this guide

Which LHON mutation was studied in the historical Lumevoq trials?
The historical RESCUE and REVERSE trials studied Lumevoq in people with the m.11778G>A mutation in the MT-ND4 gene. Because the therapy is designed to deliver a working copy of ND4, a different LHON mutation may not match the treatment being studied, and each future trial can set its own criteria.
How soon after vision loss did past Lumevoq trials treat patients?
RESCUE enrolled people whose vision loss began up to six months earlier, while REVERSE included people with approximately six to 12 months of vision loss. Together, the studies focused on treatment within one year of symptoms beginning in the first affected eye, although future trials may use different time limits.
Does an OCT scan determine whether I can join a Lumevoq trial?
OCT measures the thickness of retinal nerve fiber layers and helps clinicians assess the optic nerve. Better starting vision and thicker nerve layers were associated with better outcomes in analyses, but one thin measurement does not automatically disqualify someone; the study protocol and complete medical review determine eligibility.
Is Lumevoq approved, or are related trials currently enrolling?
Lumevoq is not currently an approved, widely available treatment, and the major RESCUE and REVERSE studies are completed. Whether a trial is actively recruiting depends on the study and location, so a clinical-trial registry or LHON specialist can confirm current options.
What options exist if my mutation or symptom timing does not fit a Lumevoq trial?
Not qualifying for one study does not mean you have no support options. Depending on your location and medical situation, clinicians may discuss idebenone, avoiding mitochondrial triggers such as smoking, genetic counseling, and low-vision rehabilitation.
What information should I bring when asking about trial eligibility?
Bring an official genetic test report, especially one showing whether you have the m.11778G>A mutation, and an estimate of when vision changes began in the first affected eye. Medical records and OCT results may also help the trial team assess your health and compare your situation with the study criteria.
Did age affect eligibility in past Lumevoq studies?
The primary analyzed populations in the pivotal studies were at least 15 years old when vision loss began. This age range was specific to those protocols, and future trials may use different age requirements.

Related questions

What Is LHON Plus and Which Symptoms Can It Cause? How Does Idebenone Treat LHON? How Long Should I Take It? Does LHON Cause Complete Blindness? Vision Loss Explained How Do LHON Mutations Differ in Prognosis and Recovery? At What Age Do LHON Symptoms Usually Begin in Carriers?
Show more
Can LHON Mothers Pass It On—and Will Children Have Symptoms? Can Fathers Pass LHON to Their Children? Inheritance Can You Still Drive with LHON? Vision and Licensing Rules How Soon Does LHON Affect the Second Eye? Typical Timeline Is Leber Hereditary Optic Neuropathy Vision Loss Painless? What Is the Bilateral Transfer Effect in LHON Gene Therapy? What Is the Spontaneous Visual Recovery Rate for LHON? What Low-Vision Help Is Available for LHON Patients? What Triggers Sudden Vision Loss in LHON Carriers? What Vitamins and Supplements Are Recommended for LHON? Why Are Smoking and Alcohol Dangerous for LHON Patients? Why Doesn't Steroid Treatment Improve LHON Vision Loss? Why Is an MRI Used for Leber Hereditary Optic Neuropathy? Why Should LHON Patients Avoid BAK-Preserved Eye Drops?

Get notified when new evidence is published on Leber hereditary optic neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (7)
  1. 1

    Intravitreal Gene Therapy vs. Natural History in Patients With Leber Hereditary Optic Neuropathy Carrying the m.11778G>A ND4 Mutation: Systematic Review and Indirect Comparison.

    Newman NJ, Yu-Wai-Man P, Carelli V, et al.

    Frontiers in neurology 2021; (12()):662838 doi:10.3389/fneur.2021.662838.

    PMID: 34108929
  2. 2

    Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset.

    Newman NJ, Yu-Wai-Man P, Carelli V, et al.

    Ophthalmology 2021; (128(5)):649-660 doi:10.1016/j.ophtha.2020.12.012.

    PMID: 33451738
  3. 3

    Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.

    Yu-Wai-Man P, Newman NJ, Carelli V, et al.

    Science translational medicine 2020; (12(573)) doi:10.1126/scitranslmed.aaz7423.

    PMID: 33298565
  4. 4

    Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates.

    Calkins DJ, Yu-Wai-Man P, Newman NJ, et al.

    Molecular therapy. Methods & clinical development 2021; (23()):307-318 doi:10.1016/j.omtm.2021.09.013.

    PMID: 34729378
  5. 5

    Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy.

    Newman NJ, Yu-Wai-Man P, Subramanian PS, et al.

    Brain : a journal of neurology 2023; (146(4)):1328-1341 doi:10.1093/brain/awac421.

    PMID: 36350566
  6. 6

    Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy.

    Yu-Wai-Man P, Newman NJ, Biousse V, et al.

    JAMA ophthalmology 2025; (143(2)):99-108 doi:10.1001/jamaophthalmol.2024.5375.

    PMID: 39699886
  7. 7

    Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy.

    Sergott RC, Carelli V, Newman NJ, et al.

    Investigative ophthalmology & visual science 2025; (66(9)):42 doi:10.1167/iovs.66.9.42.

    PMID: 40662892

This page is for informational purposes only and does not constitute medical advice. An LHON specialist or clinical-trial team should assess your mutation, symptom timeline, OCT findings, and individual risks.